Company Captor Therapeutics Spolka Akcyjna

Equities

CTX

PLCPTRT00014

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Captor Therapeutics Spolka Akcyjna

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 09:33:18 28/06/2024 pm IST			5-day change	1st Jan Change
77.4 ^PLN	-2.27%		-3.25%	-21.82%

29/05	Captor Therapeutics Spolka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Captor Therapeutics Spolka Akcyjna Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.

Number of employees: 105

PLN in Million	2022	Weight	2023	Weight	Delta
Research and Development 100.0 %	9	100.0 %	13	100.0 %	+44.15%

PLN in Million	2022	Weight	2023	Weight	Delta
Poland 100.0 %	9	100.0 %	13	100.0 %	+44.15%

Managers	Title	Age	Since
Thomas Shepherd CEO	Chief Executive Officer	-	-
Michal Jerzy Walczak CTO	Chief Tech/Sci/R&D Officer	39	22/19/22
Maria Sagan IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Krzysztof Samotij BRD	Director/Board Member	72	08/20/08
Robert Florczykowski BRD	Director/Board Member	-	01/22/01
Pawel Jerzy Holstinghausen-Holsten CHM	Chairman	52	28/18/28
Maciej Wroblewski BRD	Director/Board Member	-	17/21/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,645,712	2,353,229 ( 50.65 %)	0	50.65 %

Name	Equities	%	Valuation
Generali PTE SA 3.110 %	144,460	3.110 %	3 M zł
Allianz Polska TFI SA 2.021 %	93,910	2.021 %	2 M zł
Millennium TFI SA 0.6070 %	28,200	0.6070 %	522 886 zł
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA 0.2673 %	12,416	0.2673 %	230 218 zł
IPOPEMA TFI SA 0.2153 %	10,000	0.2153 %	185 420 zł
Pekao TFI SA 0.1242 %	5,769	0.1242 %	106 969 zł
Investors TFI SA 0.1216 %	5,650	0.1216 %	104 763 zł

Captor Therapeutics SA

ul. Dunska 11

54-427, Wroclaw

+48 53 786 9089

http://www.captortherapeutics.com

address Captor Therapeutics Spolka Akcyjna(CTX)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

77.4 PLN

Average target price

115 PLN

Spread / Average Target

+48.58%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CAPTOR THERAPEUTICS SPOLKA AKCYJNA	-21.82%	89.43M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research